

BASE MODULE: EVIDENCE BASED DECISION MAKING FOR PRICING AND REIMBURSEMENT: FROM THEORY TO PRACTICE

21–23 October 2019, Vienna

This module is designed for professionals working in the pharmaceutical and medical device industry, in the public health sector and those who are involved in negotiations and decision making for pricing and reimbursement. Those who have a need to understand how evidence based decision making is being used to direct reimbursement and market access decisions will also benefit from this course.

PROGRAM DIRECTORS:

Dominique Vandijck, MSc, PhD, Professor of Healthcare Innovation, Health Economics, Healthcare Policy & Patient Safety at the Faculty of Medicine and Life Sciences of Hasselt University, and at the Faculty of Medicine and Health Sciences, and the Faculty of Pharmacy at Ghent University (Belgium)

Jürgen Raths, MD, Chief Executive Officer of Cordée Consulting, Geneva

Heinrich Klech MD, PhD, Professor of Medicine, Medical University Vienna, Chief Executive Officer of Vienna School of Clinical Research (VSCR)

TECHNICAL COURSE DIRECTOR:

Margarete Schreiner-Karner, MSc, Chief Operations Officer of Vienna School of Clinical Research (VSCR)

DAY 1

MONDAY, 21 OCTOBER 2019

09:00–09:10	[10 min]	OPENING & INTRODUCTION Heinrich Klech , CEO VSCR (AT) Margarete Schreiner-Karner , COO VSCR (AT)	
09:10–10:30	[80 min]	1. LECTURE APPLICATION OF HEALTH TECHNOLOGY ASSESSMENT ✎ Why understanding the value and value for money of innovative pharmaceuticals and other health technologies is important! A brief history of HTA ✎ Why healthcare systems engage in HTA ✎ Assessment versus appraisal for market access ✎ Key stakeholders: EUNetHTA, ICER (US), NICE, EMA, other ISPOR top 10 HEOR trends ✎ The payer perspective: Value for money versus affordability challenge in practice. Why budget impact is important to payers	Jürgen Raths (CH)
10:30–10:45	[15 min]	Coffee break	
10:45–11:30	[45 min]	1. LECTURE CONTINUED APPLICATION OF HEALTH TECHNOLOGY ASSESSMENT ✎ Overview of country differences in the application of HTA ✎ HTA for decision/policy making: pricing and reimbursement of pharmaceuticals and recent requirements for devices ✎ Special cases: ultra- orphan drugs and regenerative medicines HTA and the patient perspective	Jürgen Raths (CH)

DAY 1 (CONTINUED)

MONDAY, 21 OCTOBER 2019

11:30–12:15	[45 min]	2. GROUP EXERCISE BREAK OUT SESSION ON HTA APPLICATIONS FOR DECISION MAKING: THE TABLE OF CONTENTS OF HTA	Jürgen Raths (CH)
12:15–12:30	[15 min]	3. KNOWLEDGE TEST	Jürgen Raths (CH)
12:30–13:30	[60 min]	Lunch break	
13:30–15:00	[120 min]	4. LECTURE HTA, PRICING AND REIMBURSEMENT: CHALLENGES OF VALUE ASSESSEMENT FRAMEWORKS ACROSS MARKETS (GERMANY, FRANCE, SWEDEN, UK)	Jürgen Raths (CH)
15:00–15:30	[30 min]	5. LECTURE CRITERIA FOR SUCCESS AND FOR PITFALLS FOR HTA SUBMISSIONS – A CASE STUDY	Jürgen Raths (CH)
15:30–16:00	[30 min]	6. LECTURE EUROPEAN PRICING CHALLENGES FOR VALUE ASSESSMENT/PRICING MODELS – CASE STUDY	Andrea Sobrio (CH)
16:00–16:30	[30 min]	Coffee break	
16:30–17:30	[60 min]	7. LECTURE KEY ELEMENTS OF A SUCCESSFUL HTA: EVIDENCE, REAL CASE STUDIES, WHAT MIGHT INFLUENCE DECISION MAKERS	Jürgen Raths (CH)

DAY 2

TUESDAY, 22 OCTOBER 2019

09:00–09:20	[20 min]	OPENING & INTRODUCTION	Heinrich Klech (AT)/Margarete Schreiner-Karner (AT)
09:20–10:50	[90 min]	8. LECTURE HEALTH ECONOMIC EVALUATIONS CONCEPTS AND PRINCIPLES	Dominique Vandijck (BE)
10:50–11:15	[25 min]	Coffee break	
11:15–12:15	[60 min]	9. LECTURE HEALTH ECONOMIC MODELS 1, CONCEPTS, PRINCIPLES OF DECISION TREES	Dominique Vandijck (BE)
12:15–13:15	[60 min]	Lunch break	
13:15–15:00	[105 min]	10. LECTURE HEALTH ECONOMIC MODELS 2, CONCEPTS AND PRINCIPLES OF MARKOV MODELS	Dominique Vandijck (BE)
15:00–16:30	[90 min]	11. GROUP EXERCISE DESIGN A MODEL	Dominique Vandijck (BE)
16:30–17:00	[30 min]	Coffee break	
17:00–17:30	[30 min]	12. KNOWLEDGE TEST	Dominique Vandijck (BE)

DAY 3

WEDNESDAY, 23 OCTOBER 2019

09:00–09:30	(30 min)	13. LECTURE ASSESSING AND INTERPRETING THE VALUE OF ORPHAN DRUGS	Anna Bucsics (AT)
09:30–10:00	(30 min)	14. LECTURE EUNetHTA AND ITS ROLE – THE PURPOSE OF JOINT EMA-HTA SCIENTIFIC ADVICE	Claudia Wild (AT)
10:00–10:30	(30 min)	15. KNOWLEDGE TEST	Anna Bucsics (AT)/Claudia Wild (AT)
10:30–11:30	(60 min)	Coffee break	
11:30–12:00	(30 min)	16. KEY NOTE LECTURE OPENING AND INTRODUCTION Alfred Pritz , Rektor SFU KEY NOTE LECTURE UNLOCKING THE FULL POTENTIAL OF GENERIC AND BIOSIMILAR MEDICINES TO ENABLE PATIENT ACCESS TO MEDICINES Maarten van Baelen , Market Access Director at Medicines for Europe, Belgium	
12:00–14:00	(120 min)	17. PANEL DISCUSSION UNLOCKING THE FULL POTENTIAL OF GENERIC AND BIOSIMILAR MEDICINES TO ENABLE PATIENT ACCESS TO MEDICINES	Chair: Rok Hren (Slovenia)
Invited participants:		Maarten van Baelen (Market Access Director at Medicines for Europe, Belgium) Marcin Czech (Head of the Department of Pharmacoeconomics at the Institute of Mother and Child in Warsaw, President-elect of ISPOR, Poland Chapter, former Undersecretary of State/Vice Minister at Ministry of Health) Rok Hren (Head of Laboratory Diagnostics & Point of Care & Molecular Diagnostics – Slovenia & Adriatic Region at Siemens Healthineers and President of ISPOR Slovenia Regional Chapter, Chair-Elect ISPOR CEE) Wolfgang Wein (Managing Director Merck GmbH, Austria) Anna Bucsics (Project Advisor at MoCA – Mechanism of Coordinated Access to Orphan Medicinal Products, Austria) Ernst Agneter (Chairman of the Association of the Austrian Pharmaceutical Industry-working group Health Economics & Reimbursement) Vladimir Kopernicky (Vice President, International Medical Affairs, Eli Lilly)	
14:00–15:00	(60 min)	Lunch break	
15:00–16:00	(60 min)	CLOSING REMARKS, PLUS EVALUATION OF STUDENTS ASSESSMENTS AND HANDOVER OF CERTIFICATES AND AWARDS	Heinrich Klech (AT)